Enjoy complimentary customisation on priority with our Enterprise License!
The global humanized mouse model market size is estimated to grow by USD 108.6 million at a CAGR of 10.22% between 2023 and 2028.
Personalized medicine, also called precision medicine or individualized medicine, is an emerging field of medicine. It identifies specific biomarkers to assess the best treatment for each patient. Mice have been used to develop personalized medicine for cancer. patient's tumor is infused into multiple and identical mice, which have compromised immune systems. Each mouse receives a different therapy, and each therapy is then assessed. The therapy that reduces the tumor would then be directed to the patient. The growing demand for personalized medicine will increase the adoption of humanized mouse models. Hence, such factors are expected to drive the growth of the market during the forecast period.
Technavio has segmented the market into End-user, Product, and Geography
It also includes an in-depth analysis of drivers, trends, and challenges. Our report examines historical data from 2018-2022, besides analyzing the current market scenario.
To learn more about this report, Download Report Sample
The market share growth by the pharmaceutical and biotechnology companies segment will be significant during the forecast period. Pharmaceutical and biotechnology companies use humanized mouse models to study human diseases and test potential treatments. In the pharmaceutical industry, humanized mouse models are used in the early stages of drug development to identify potential drug targets and test the safety and efficacy of new drugs.
Get a glance at the market contribution of various segments Download the PDF Sample
The pharmaceutical and biotechnology companies segment was valued at USD 47.54 million in 2018. In the biotechnology industry, humanized mouse models are used to develop and test new biologics, such as monoclonal antibodies and cell therapies. Furthermore, the use of humanized mouse models in the pharmaceutical and biotechnology industries has become increasingly important in recent years, as these models provide more accurate and predictive results compared to traditional animal models. Therefore, such factors are expected to drive the growth of the segment during the forecast period.=
In genetically modified mouse models, a specific gene is removed or replaced. These models are effective tools for several applications in molecular research and drug discovery. Due to the growth of the global molecular and genetic research industries, the adoption of genetically humanized mouse models is anticipated to increase. Furthermore, market players have streamlined the genetic engineering process in-house. Hence, ready-to-use mouse models are available for researchers. Product innovations have enabled researchers to choose disease-specific mouse models. Therefore, such factors are expected to drive the growth of this segment of the market during the forecast period.
Cell-based humanized mouse models are structured differently when compared with genetically humanized mouse models. They are infused with various cell types to cure infectious diseases. With the growing prevalence of infectious diseases around the globe, the demand for cell-based humanized mouse models is expected to increase during the forecast period. Furthermore, product innovations are driving the demand for cell-based humanized mouse models. For instance, JAX offers models such as the Hu-CD34-NSG and Hu-CD34-SGM3, which are suited for the long-term study of infectious diseases. Thus, due to the growth in the number of applications of cell-based humanized mouse models, their adoption is expected to increase during the forecast period.
For more insights about the market share of various regions Download PDF Sample now!
Europe is estimated to contribute 34% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. Another region offering significant growth opportunities to market players is North America. As developed healthcare systems can be found in nations like the US and Canada, North America held the top position in terms of revenue in 2022. One of the main factors influencing the market in North America is the high cost of healthcare research.
Furthermore, the region is characterized by the presence of vendors such as Taconic, JAX, Champions Oncology Inc. (Champions Oncology), HuMurine Technologies (HuMurine), and ingenious targeting laboratories. High vendor penetration in the US and Canada will increase product availability and sales. Hence, such factors will fuel the regional market growth during the forecast period.
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:
Altogen labs: The company offers humanized mouse model which are commonly used to test out cancer therapies and drugs, as they are relatively cheap and efficient when compared to humans.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
There are multiple factors influencing the market growth. Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges.
The growing adoption of personalized medicine is notably driving market growth. A new area of medicine is personalized medicine, also known as precision medicine or individualized medicine. To determine the best course of action for each patient, it pinpoints specific biomarkers. Cancer treatment personalized medicine has been created by using mice. The PDX cancer model has been developed by researchers. Several identical mice with compromised immune systems are infused with various tumor-related components from the patient. Each therapy is administered to a different mouse, and each therapy is then evaluated. The patient would then receive therapy that shrinks the tumor.
Moreover, the use of humanized mouse models will rise in response to the rising demand for personalized medicine. For instance, acute myeloid leukemia (AML) and bladder, breast, lung, pancreatic, and ovarian cancers are just a few of the conditions for which Jackson Laboratory has created more than 450 distinct PDX oncology mouse models. Moreover, the advancement of personalized medicine has accelerated as a result of improvements in scientific research and related tools and technologies. Hence, these factors are expected to drive the growth of the market during the forecast period.
Strategic alliances of vendors is the primary trend shaping market growth. Market players are focusing on developing new strategies to gain a competitive advantage and retain their dominant position. In addition, they are focusing on partnerships to improve their product offerings and expand their customer base via new distribution channels. Some recent strategic alliances in the global humanized mouse model market include:
For instance, in May 2021, Heligenics, Inc. signed a new collaboration with The Jackson Laboratory (JAX). This collaboration includes licensing a custom Heligenics Gene Mutation/Function ERBB2 library for the JAX clinical knowledge base. Thus, such factors are expected to drive the growth of the market during the forecast period.
Limitations of humanized mouse models is a challenge that affects market growth. Humanized mouse models are extensively used for HIV and cancer research. However, to date, the current models that have been developed have major scientific drawbacks, which are affecting their adoption. During multiple research studies, these models do not correctly exhibit genetic and proteomic responses. These irregularities contribute to the generation of incorrect insights, which affects the outcomes of experiments. Moreover, mouse models have also been found to be ineffective in three conditions, which include burns, sepsis, and trauma. Researchers have constantly expressed concerns about the significant spending on humanized mouse models, which were ineffective for certain diseases.
However, although mouse models have contributed significantly to HIV and cancer research, some models still lack the ability to address common human conditions such as sepsis and trauma. When they elicit different genomic responses from humans, the treatment response is also altered. In most cases, when the supposed cure is induced in humans, it may lead to fatal responses. Thus, to avoid the loss of money, time, and patient pool, researchers may look for other methods to cure such diseases, which impede the growth of the market during the forecast period.
The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Global Humanized Mouse Model Market Customer Landscape
The humanized mouse model market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2018 to 2028.
Humanized Mouse Model Market Scope |
|
Report Coverage |
Details |
Page number |
160 |
Base year |
2023 |
Historic period |
2018-2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 10.22% |
Market Growth 2024-2028 |
USD 108.6 million |
Market structure |
Fragmented |
YoY growth 2023-2024(%) |
9.72 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
Europe at 34% |
Key countries |
US, UK, France, China, and Japan |
Competitive landscape |
Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks |
Key companies profiled |
Altogen labs, Aragen Life Sciences Pvt. Ltd., Biocytogen, BioSafety Research Center Inc., Champions Oncology Inc., Charles River Laboratories International Inc., Creative Biolabs, Cyagen Biosciences, Gempharmatech Co. Ltd., genOway, HBM Holdings Ltd., Hera Biolabs Inc., ingenious targeting laboratory, Inotiv, Inc., JANVIER LABS, JSR Corp., Oncodesign SA, Ozgene Pty Ltd., PerkinElmer Inc., and Pharmatest services |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and market condition analysis for the forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Download Sample PDF at your Fingertips
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by End-user
7 Market Segmentation by Product
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.